Subcutaneous delivery of biotherapeutics has become a valuable alternative to intravenous
administration across many disease areas. Although the pharmacokinetic profiles of …

The glycosaminoglycan hyaluronan (HA), a major component of extracellular matrices, and
cell surface receptors of HA have been proposed to have pivotal roles in cell proliferation …

The continued evolution of biomedical nanotechnology has enabled clinicians to better
detect, prevent, manage, and treat human disease. In order to further push the limits of …

There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion
molecule with the primary determinant being FcRn-mediated recycling. Through Fab or Fc …

The progress in microneedle research is evidenced by the transition from simple 'poke and
patch'solid microneedles fabricated from silicon and stainless steel to the development of …

Tumors are similar to organs, with unique physiology giving rise to an unusual set of
transport barriers to drug delivery. Cancer therapy is limited by nonuniform drug delivery via …

There is considerable interest in the pharmaceutical industry toward development of
antibody-based biotherapeutics because they can selectively bind diverse receptors and …

The convenience of subcutaneous (SC) administration and the increasing interest in
monoclonal antibody (mAb)-based therapies for chronic diseases, hint their potential for SC …

Background A subcutaneous formulation of trastuzumab has been developed, offering
potential improvements in patient convenience and resource use compared with the …

The subcutaneous (SC) route is of growing interest for the administration of biotherapeutics.
Key products on the biotherapeutic market such as insulins, but also several …